News
Stay up to date with the latest developments from OrchestratePharma.
OrchestratePharma establishes SPV (subsidiary) in Sweden
Celfex AB has sub-licensed from OrchestratePharma the right to develop fexofenadine. A topical formulation of fexofenadine shall target mild to medium atopic dermatitis. Celfex AB shall enter a Phase 2 clinical study together with several co-development CRO partners in Asia and Europe.
Fexofenadine (Celfex) Key Mechanisms
H1R Blocking
Potent H1 receptor antagonism reduces histamine-mediated itch and inflammation.
Anti-inflammatory
Demonstrated anti-inflammatory properties beyond antihistamine effects, reducing cytokine production.
Dysbiosis Correction
Potential to restore healthy skin microbiome balance disrupted in eczema and other skin conditions.
Moisture Retention
Supports skin barrier function and helps maintain proper hydration levels.
Barrier Repair
Promotes restoration of the skin's natural protective barrier compromised in dermatological conditions.
Antimicrobial
Exhibits antimicrobial properties that may help prevent secondary infections in damaged skin.